Patient perspectives on switching disease-modifying therapies in the NARCOMS registry.

Salter, Amber R; Marrie, Ruth Ann; Agashivala, Neetu; Belletti, Daniel A; Kim, Edward; Cutter, Gary R; Cofield, Stacey S; Tyry, Tuula

Salter, Amber R; Marrie, Ruth Ann; Agashivala, Neetu; Belletti, Daniel A; Kim, Edward; Cutter, Gary R; Cofield, Stacey S; Tyry, Tuula.

Afiliación

Salter AR; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Marrie RA; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada ; Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Agashivala N; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Belletti DA; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Kim E; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Cutter GR; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Cofield SS; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Tyry T; Division of Neurology, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.

Patient Prefer Adherence ; 8: 971-9, 2014.

Article en En | MEDLINE | ID: mdl-25045254

Palabras clave

health communication; multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Patient Prefer Adherence Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google